Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
AB

NASDAQ · ABSI

Absci Corporation

Healthcare · Biotechnology

$11.13

Down-$0.97 (-8.02%)

Updated Nov 1, 2026, 7:23 PM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
412.02M
P/E ratio
-3.44
Dividend yield
0.00%
52-week range
$2.24 – $12.54
Volume
4.57M
Avg. volume
3.49M

Price performance · ABSI

ABSI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ABSI closed at $11.13 after 20 trading sessions, down 3.47% for the selected period.

Last close
$11.13
Period change
-3.47%
Period low
$8.25
Period high
$12.10
Daily close
View OHLC price history
ABSI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$11.41$11.80$10.4501$11.134.57M
Oct 29, 2026$11.97$12.5449$11.91$12.104.34M
Oct 28, 2026$10.55$11.89$10.43$11.885.83M
Oct 27, 2026$9.54$10.95$9.36$10.575.84M
Oct 26, 2026$9.20$9.76$9.03$9.453.37M
Oct 23, 2026$9.28$9.35$8.965$9.181.89M
Oct 22, 2026$9.69$9.95$8.93$9.373.71M
Oct 21, 2026$9.24$10.205$9.1137$10.045.35M
Oct 20, 2026$8.465$9.10$8.22$9.072.83M
Oct 19, 2026$8.69$8.96$8.395$8.542.76M
Oct 16, 2026$8.93$8.95$8.12$8.253.55M
Oct 15, 2026$8.43$8.945$8.23$8.883.4M
Oct 14, 2026$8.88$9.12$8.62$8.743.56M
Oct 13, 2026$9.445$9.66$9.00$9.103.05M
Oct 12, 2026$10.065$10.09$9.43$9.672.86M
Oct 9, 2026$9.20$10.3902$8.93$10.164.25M
Oct 8, 2026$9.04$9.27$8.81$8.944.68M
Oct 7, 2026$10.00$10.22$9.1201$9.225.85M
Oct 6, 2026$11.77$11.89$10.21$10.275.88M
Oct 5, 2026$11.105$11.80$10.87$11.534.29M

Latest ABSI news

The latest Smart Investors Daily articles mentioning ABSI.

Stock researchCompany · Overview

ABSI research

Overview

Company profile and research snapshot.

Company profile

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$6.00
Implied upside
—
Analysts
15
ABSI recent ratings
DateFirmRatingTarget
Oct 29, 2026JefferiesBuy—
Oct 16, 2026KeybancOverweight—
Oct 12, 2026JP MorganOverweight—
Oct 12, 2026HC Wainwright & Co.Buy—
Sep 23, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference (Boston, MA)Fireside chat on Tuesday, November 10th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time 2026 Jefferies Global Healthcare Con

Yahoo · Oct 24, 2026

Is Absci (ABSI) Undervalued As Positive ABS 201 Phase 1 Data Lifts Optimism?

Absci (ABSI) has drawn fresh attention after reporting positive interim Phase 1 data for ABS-201 in pattern hair loss, including an estimated half-life of at least 65 days for the antibody therapy. The latest ABS-201 update lands after a powerful run for Absci’s stock, with a year-to-date share price return of 154.29% and a 1-year total shareholder return of 114.99% that has reshaped how the market prices its pipeline risk. Scan Absci’s momentum against a curated field of biotech names by...

Yahoo · Oct 16, 2026

Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop

Absci has posted very strong multi year share gains, and the jump in market value now raises a simple question for you as an investor. Is the current price still grounded in what the business has built on its balance sheet, or has it moved well ahead of its book value? Over the past 3 years, Absci has delivered a very large share price gain, which puts extra focus on whether that move lines up with the strength of its underlying net assets. The business relies on capital intensive research...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By